Bakgrunn
Caroline Stokke er seksjonsleder på nukleærmedisinsk fysikk ved Oslo Universitetssykehus (OUS), og har en bistilling ved UiO. Hun er forskningsleder for Theragnostic Imaging gruppen ved OUS (ekstern nettside).
Faglige interesser
Nukleærmedisinsk diagnostikk og terapi, dosimetri, strålingsfysikk og bildedannende modaliteter.
Undervisning
FYS4762 – Medisinsk avbildning med ioniserende stråling - Universitetet i Oslo (uio.no) / FYS9762 – Medisinsk avbildning med ioniserende stråling - Universitetet i Oslo (uio.no)
Verv
Nestleder av EANMs dosimetrikomité (ekstern nettside)
Styremedlem i EFOMPs "Radionuclide Internal Dosimetry" gruppe (ekstern nettside)
Publikasjoner
-
Blakkisrud, Johan; Peterson, Avery B.; Wildermann, Scott J.; Kingkiner, Griffen; Wong, Ka Kit & Wang, Chang
[Vis alle 9 forfattere av denne artikkelen]
(2024).
SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [<sup>177</sup>Lu]Lu-DOTATATE.
Journal of Nuclear Medicine.
ISSN 0161-5505.
65(5),
s. 753–760.
doi:
10.2967/jnumed.123.266843.
-
-
-
-
-
-
Afroz, Susmita; Østerås, Bjørn Helge; Thevathas, Utheya Salini; Døhlen, Gaute; Stokke, Caroline & Robsahm, Trude Eid
[Vis alle 7 forfattere av denne artikkelen]
(2023).
Use of ionizing radiation in a Norwegian cohort of children with congenital heart disease: imaging frequency and radiation dose for the Health Effects of Cardiac Fluoroscopy and Modern Radiotherapy in Pediatrics (HARMONIC) study.
Pediatric Radiology.
ISSN 0301-0449.
53,
s. 2502–2514.
doi:
10.1007/s00247-023-05774-8.
Fulltekst i vitenarkiv
Vis sammendrag
Background: The European-funded Health Effects of Cardiac Fluoroscopy and Modern Radiotherapy in Pediatrics (HAR-
MONIC) project is a multicenter cohort study assessing the long-term effects of ionizing radiation in patients with congenital
heart disease. Knowledge is lacking regarding the use of ionizing radiation from sources other than cardiac catheterization
in this cohort.
Objective: This study aims to assess imaging frequency and radiation dose (excluding cardiac catheterization) to patients
from a single center participating in the Norwegian HARMONIC project.
Materials and methods: Between 2000 and 2020, we recruited 3,609 patients treated for congenital heart disease
(age < 18 years), with 33,768 examinations categorized by modality and body region. Data were retrieved from the radiology
information system. Effective doses were estimated using International Commission on Radiological Protection Publication
60 conversion factors, and the analysis was stratified into six age categories: newborn; 1 year, 5 years, 10 years, 15 years,
and late adolescence.
Results: The examination distribution was as follows: 91.0% conventional radiography, 4.0% computed tomography (CT),
3.6% diagnostic fluoroscopy, 1.2% nuclear medicine, and 0.3% noncardiac intervention. In the newborn to 15 years age cat-
egories, 4–12% had ≥ ten conventional radiography studies, 1–8% underwent CT, and 0.3–2.5% received nuclear medicine
examinations. The median effective dose ranged from 0.008–0.02 mSv and from 0.76–3.47 mSv for thoracic conventional
radiography and thoracic CT, respectively. The total effective dose burden from thoracic conventional radiography ranged
between 28–65% of the dose burden from thoracic CT in various age categories (40% for all ages combined). The median
effective dose for nuclear medicine lung perfusion was 0.6–0.86 mSv and for gastrointestinal fluoroscopy 0.17–0.27 mSv.
Because of their low frequency, these procedures contributed less to the total effective dose than thoracic radiography.
Conclusion This study shows that CT made the largest contribution to the radiation dose from imaging (excluding cardiac
intervention). However, although the dose per conventional radiograph was low, the large number of examinations resulted
in a substantial total effective dose. Therefore, it is important to consider the frequency of conventional radiography while
calculating cumulative dose for individuals. The findings of this study will help the HARMONIC project to improve risk
assessment by minimizing the uncertainty associated with cumulative dose calculations
-
Mikalsen, Lars Tore Gyland; Kvassheim, Monika & Stokke, Caroline
(2023).
Optimized SPECT Imaging of 224Ra α-Particle Therapy by 212Pb Photon Emissions.
Journal of Nuclear Medicine.
ISSN 0161-5505.
64(7),
s. 1131–1137.
doi:
10.2967/jnumed.122.264455.
Fulltekst i vitenarkiv
-
-
Bruvoll, Ragnar Bjørn Watte; Blakkisrud, Johan; Mikalsen, Lars Tore Gyland; Connelly, James Pattrick & Stokke, Caroline
(2023).
Correlations between 68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE.
Cancers.
ISSN 2072-6694.
15(4).
doi:
10.3390/cancers15041134.
Fulltekst i vitenarkiv
-
Cicone, Francesco; Santo, Giulia; Bodet-Milin, Caroline; Cascini, Giuseppe Lucio; Kraeber-Bodéré, Françoise & Stokke, Caroline
[Vis alle 7 forfattere av denne artikkelen]
(2023).
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.
Seminars in nuclear medicine.
ISSN 0001-2998.
53(3),
s. 413–425.
doi:
10.1053/j.semnuclmed.2022.12.006.
Vis sammendrag
Systemic radioimmunotherapy (RIT) is arguably the most effective and least toxic anticancer treatment for non-Hodgkin lymphoma (NHL). In treatment-naïve patients with indolent NHL, the efficacy of a single injection of RIT compares with that of multiple cycles of combination chemotherapy. However, 20 years following the approval of the first CD20-targeting radioimmunoconjugates 90Y-Ibritumomab-tiuxetan (Zevalin) and 131I-tositumomab (Bexxar), the number of patients referred for RIT in western countries has dramatically decreased. Notwithstanding this, the development of RIT has continued. Therapeutic targets other than CD20 have been identified, new vector molecules have been produced allowing for faster delivery of RIT to the target, and innovative radionuclides with favorable physical characteristics such as alpha emitters have been more widely available. In this article, we reviewed the current status of RIT in NHL, with particular focus on recent clinical and preclinical developments.
-
-
-
Kvassheim, Monika; Rootwelt-Revheim, Mona Elisabeth & Stokke, Caroline
(2022).
Quantitative SPECT/CT imaging of lead-212: a phantom study.
EJNMMI Physics.
ISSN 2197-7364.
9(1).
doi:
10.1186/s40658-022-00481-z.
Vis sammendrag
Background
Lead-212 (212Pb) is a promising radionuclide for targeted therapy, as it decays to α-particle emitter bismuth-212 (212Bi) via β-particle emission. This extends the problematic short half-life of 212Bi. In preparation for upcoming clinical trials with 212Pb, the feasibility of quantitative single photon-emission computed tomography/computed tomography (SPECT/CT) imaging of 212Pb was studied, with the purpose to explore the possibility of individualised patient dosimetric estimation.
Results
Both acquisition parameters (combining two different energy windows and two different collimators) and iterative reconstruction parameters (varying the iterations x subsets between 10 × 1, 15 × 1, 30 × 1, 30 × 2, 30 × 3, 30 × 4, and 30 × 30) were investigated to evaluate visual quality and quantitative uncertainties based on phantom images. Calibration factors were determined using a homogeneous phantom and were stable when the total activity imaged exceeded 1 MBq for all the imaging protocols studied, but they increased sharply as the activity decayed below 1 MBq. Both a 20% window centred on 239 keV and a 40% window on 79 keV, with dual scatter windows of 5% and 20%, respectively, could be used. Visual quality at the lowest activity concentrations was improved with the High Energy collimator and the 79 keV energy window. Fractional uncertainty in the activity quantitation, including uncertainties from calibration factors and small volume effects, in spheres of 2.6 ml in the NEMA phantom was 16–21% for all protocols with the 30 × 4 filtered reconstruction except the High Energy collimator with the 239 keV energy window. Quantitative analysis was possible both with and without filters, but the visual quality of the images improved with a filter.
Conclusions
Only minor differences were observed between the imaging protocols which were all determined suitable for quantitative imaging of 212Pb. As uncertainties generally decreased with increasing iterative updates in the reconstruction and recovery curves did not converge with few iterations, a high number of reconstruction updates are recommended for quantitative imaging.
-
-
Løndalen, Ayca; Blakkisrud, Johan; Rootwelt-Revheim, Mona Elisabeth; Dahle, Jostein; Kolstad, Arne & Stokke, Caroline
(2022).
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?
Molecular Imaging and Biology.
ISSN 1536-1632.
s. 807–817.
doi:
10.1007/s11307-022-01731-3.
Fulltekst i vitenarkiv
-
-
-
-
Chiesa, Carlo; Sjogreen-Gleisner, Katarina; Walrand, Stephan; Strigari, Lidia; Flux, Glenn & Gear, Jonathan
[Vis alle 10 forfattere av denne artikkelen]
(2021).
EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres.
EJNMMI Physics.
ISSN 2197-7364.
8,
s. 1–44.
doi:
10.1186/s40658-021-00394-3.
-
-
Müller, Ebba Gløersen; Stokke, Caroline; Stokmo, Henning Langen; Edwin, Trine Holt; Knapskog, Anne Brita & Rootwelt-Revheim, Mona Elisabeth
(2021).
Evaluation of semi-quantitative measures of 18F-Flutemetamol PET for the clinical diagnosis of Alzheimer’s disease.
Quantitative Imaging in Medicine and Surgery (QIMS).
ISSN 2223-4292.
12(1).
doi:
10.21037/qims-21-188.
Fulltekst i vitenarkiv
-
Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Kolstad, Arne & Stokke, Caroline
(2021).
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable.
Acta Oncologica.
ISSN 0284-186X.
60(11),
s. 1481–1488.
doi:
10.1080/0284186X.2021.1959635.
Fulltekst i vitenarkiv
-
-
-
Kolstad, Arne; Illidge, Tim; Bolstad, Nils; Spetalen, Signe; Madsbu, Ulf Erik & Stokke, Caroline
[Vis alle 19 forfattere av denne artikkelen]
(2020).
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Blood Advances.
ISSN 2473-9529.
4(17),
s. 4091–4101.
doi:
10.1182/bloodadvances.2020002583.
Vis sammendrag
For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the "cold" anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with ≥2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL ≥2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171.
-
-
-
-
Halsne, Trygve; Müller, Ebba Gløersen; Spiten, Ann-Eli; Sherwani, Alexander Gul; Mikalsen, Lars Tore G & Rootwelt-Revheim, Mona-Elisabeth
[Vis alle 7 forfattere av denne artikkelen]
(2018).
The effect of new formulas for lean body mass on lean- body-mass-normalized SUV in oncologic 18F-FDG PET/CT.
Journal of Nuclear Medicine Technology.
ISSN 0091-4916.
46(3),
s. 253–259.
doi:
10.2967/jnmt.117.204586.
-
-
-
Ausland, Line; Rootwelt-Revheim, Mona-Elisabeth; Skretting, Arne & Stokke, Caroline
(2018).
Respiratory motion during 90Yttrium PET contributes to underestimation of tumor dose and overestimation of normal liver tissue dose.
Acta Radiologica.
ISSN 0284-1851.
59(2),
s. 132–139.
doi:
10.1177/0284185117710052.
-
-
-
Blakkisrud, Johan; Løndalen, Ayca Muftuler; Dahle, Jostein; Turner, Simon R.; Holte, Harald & Kolstad, Arne
[Vis alle 7 forfattere av denne artikkelen]
(2017).
Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma
Patients Treated with 177Lu-Lilotomab Satetraxetan,
a Novel Anti-CD37 Antibody–Radionuclide Conjugate.
Journal of Nuclear Medicine.
ISSN 0161-5505.
58(1),
s. 55–61.
doi:
10.2967/jnumed.116.180471.
-
Blakkisrud, Johan; Løndalen, Ayca Muftuler; Martinsen, Anne Catrine Trægde; Dahle, Jostein; Holtedahl, Jon Erik & Bach-Gansmo, Tore
[Vis alle 9 forfattere av denne artikkelen]
(2017).
Tumor absorbed dose for non-Hodgkin’s lymphoma patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan.
Journal of Nuclear Medicine.
ISSN 0161-5505.
58(1),
s. 48–54.
doi:
10.2967/jnumed.116.173922.
-
-
Rein, Idun Dale; Stokke, Caroline; Jalal, Marwa; Myklebust, June; Patzke, Sebastian & Stokke, Trond
(2015).
New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX.
Cell Cycle.
ISSN 1538-4101.
14(20),
s. 3261–3269.
doi:
10.1080/15384101.2015.1087617.
Fulltekst i vitenarkiv
-
-
Gulliksrud, Kristine; Stokke, Caroline & Martinsen, Anne Catrine Trægde
(2014).
How to measure CT image quality: Variations in CT-numbers, uniformity and low contrast resolution for a CT quality assurance phantom.
Physica Medica.
ISSN 1120-1797.
30(4),
s. 521–526.
doi:
10.1016/j.ejmp.2014.01.006.
-
Stokke, Caroline; Flåtten, Ingvild & Skarstad, Kirsten
(2012).
An Easy-To-Use Simulation Program Demonstrates Variations in Bacterial Cell Cycle Parameters Depending on Medium and Temperature.
PLOS ONE.
ISSN 1932-6203.
7(2).
doi:
10.1371/journal.pone.0030981.
-
-
Stokke, Caroline; Waldminghaus, Torsten & Skarstad, Kirsten
(2011).
Replication patterns and organization of replication forks in Vibrio cholerae.
Microbiology (Reading).
ISSN 1350-0872.
157,
s. 695–708.
doi:
10.1099/mic.0.045112-0.
Se alle arbeider i Cristin
-
-
Gear, Jonathan; Stokke, Caroline; Terwinghe, Christelle; Gnesin, Silvano; Sandström, Mattias & Tran‑Gia, Johannes
[Vis alle 13 forfattere av denne artikkelen]
(2023).
Correction to: EANM enabling guide: how to improve the accessibility of clinical dosimetry (European Journal of Nuclear Medicine and Molecular Imaging, (2023), 50, 7, (1861-1868), 10.1007/s00259-023-06226-z).
European Journal of Nuclear Medicine and Molecular Imaging.
ISSN 1619-7070.
50(10),
s. 3157–3158.
doi:
10.1007/s00259-023-06304-2.
-
-
Kvassheim, Monika; Rootwelt-Revheim, Mona Elisabeth & Stokke, Caroline
(2022).
Correction to: Quantitative SPECT/CT imaging of lead-212: a phantom study (EJNMMI Physics, (2022), 9, 1, (52), 10.1186/s40658-022-00481-z).
EJNMMI Physics.
ISSN 2197-7364.
9(1).
doi:
10.1186/s40658-022-00499-3.
-
Walrand, Stephan; Chiesa, Carlo; Gabina, Pablo Minguez; Chouin, Nicolas; Gear, Jonathan & Stokke, Caroline
[Vis alle 10 forfattere av denne artikkelen]
(2019).
Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Journal of Vascular and Interventional Radiology.
ISSN 1051-0443.
30(12),
s. 2047–2048.
doi:
10.1016/j.jvir.2019.08.030.
-
Kataike, Mercy; Whittaker, Matt; Andersen, Hilde Kjernlie; Stokke, Caroline & Martinsen, Anne Catrine Trægde
(2019).
CT Image quality for five different metal artifact reduction algorithms.
-
Mikalsen, Lars Tore Gyland; Arnesen, Marius Røthe; Bogsrud, Trond Velde; Dale, Einar & Stokke, Caroline
(2017).
Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer.
Acta Oncologica.
ISSN 0284-186X.
doi:
10.1080/0284186X.2017.1286384.
-
Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Holthe, Harald & Kolstad, Arne
[Vis alle 7 forfattere av denne artikkelen]
(2017).
Pre-dosing with lilotomab prior to antibody-radionuclide conjugate therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumour to red marrow absorbed dose in non-Hodgkin lymphoma patients.
-
Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Holthe, Harald & Kolstad, Arne
[Vis alle 7 forfattere av denne artikkelen]
(2017).
Image-based red marrow dosimetry of multiple skeletal sites for 177Lu-Lilotomab satetraxetan patients.
-
Mikalsen, Lars Tore Gyland; Arnesen, Marius R?the; Bogsrud, Trond Velde; Dale, Einar & Stokke, Caroline
(2017).
Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer.
Acta Oncologica.
ISSN 0284-186X.
56(6),
s. 894–897.
doi:
10.1080/0284186X.2017.1286384.
-
Larsen, Camilla Kjellstad; Aalen, John; Stokke, Caroline; Fjeld, Jan Gunnar; Kongsgård, Erik & Smiseth, Otto A.
[Vis alle 7 forfattere av denne artikkelen]
(2016).
Regional myocardial work by magnetic resonance imaging and noninvasive left ventricular pressure: a feasibility study in left bundle branch block.
-
Kolstad, Arne; Madsbu, Ulf Erik; Stokke, Caroline; Bach-Gansmo, Tore & Løndalen, Ayca Muftuler
(2016).
Pre-dosing with unlabelled antibody significantly increases the pharmacokinetic exposure and reduces haematological toxicity of 177Lu-lilotomab in non-Hodgkin B-cell lymphoma patients.
-
Stokke, Caroline; Løndalen, Ayca; Dahle, Jostein; Blakkisrud, Johan; Bach-Gansmo, Tore & Holtedahl, Jon Erik
[Vis alle 10 forfattere av denne artikkelen]
(2015).
Tumour-Absorbed Dose for Patients in a Phase I study undergoing antibody-radionuclide-conjugate (ARC) therapy with 177Lu-DOTA-HH1.
Se alle arbeider i Cristin
Publisert
6. nov. 2020 09:42
- Sist endret
19. sep. 2022 15:04